Francesco Ravera, MD, PhD, on the Rationale for Comparing cfDNA to MRI for Predicting pCR After Neoadjuvant Therapy in Breast Cancer

Video

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss a study that looked at cell-free DNA assessment compared with traditional MRI for determining pathological complete response in patients with locally advanced breast cancer.

CancerNetwork® sat down with Francesco Ravera, MD, PhD, fellow in the Department of Internal Medicine at the University of Genoa in Italy, to discuss research that was presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. The research examined plasma cell-free DNA as an accurate alternative for assessing pathological complete response following neoadjuvant chemotherapy in patients with locally advanced breast cancer. To understand why the investigators looked into this comparison with traditional MRI, Ravera explained the rationale for their hypothesis.

Transcription:

Today, the standard of care for the assessment of response to neoadjuvant chemotherapy in [patients with breast cancer] is based on magnetic resonance imaging, MRI, which is the best radiological procedure for this purpose but presents data [with] suboptimal accuracy, especially in regard to the assessment of [nodal disease]. In radiological complete responders, [this requires] the assessment of nodal disease biopsy and lymph node biopsy, which is not as invasive as complete resection, but may cause collateral side effects. On the other end, cell-free DNA integrity has already shown potential for diagnostic and predictive purposes in breast cancer.

Reference

Cirmena G, Ferrando L, Ravera F, et al. Plasma cell-free DNA integrity predicts the achievement of pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract LB063.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content